References
- Jones P. Haemophilia: a global challenge. Haemophilia 1995, 1: 11–13.
- Hilgartner M, Aledort L, Andes A, Gill J, and the members of the aPCC Study Group. Efficacy and safety of vapor- heated anti-inhibitor coagulant complex in haemophilia patients. Transfusion 1990; 30: 626–630.
- Hilgartner MW, Knatterud GL and the aPCC Study Group. The use of Factor eight inhibitor by-passing activity (aPCC Immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors. Blood 1983; 61: 36–40.
- Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P and the members of the French aPCC study group. Multicenter retrospective study on the utilisation of aPCC in France in patients with Factor VIII and Factor IX inhibitors. Thrombosis and Haemostasis 1997; 77: 1113–1119.
- Negrier C, Lee M et al. The FEIBA-VH survey: Initial findings from a world-wide surveillance study. Haemophilia 2000; 6 (Suppl. 1): 279–314
- Lusher JM. Early treatment with recombinant Factor VIIa results in greater efficacy with less product. European Journal of Haematology 1998; 61 (Suppl. 63): 7–10.
- Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated Factor VII in patients with Factor VIII inhibitors: the advantages of early intervention. British Journal of Haematology 1999; 104: 22–26.
- Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant Factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thrombosis and Haemostasis 1998; 80: 912–918.
- Lipton RA. The economics of Factor VIII inhibitor treatment. Seminars in Haematology 1994; 31 (Suppl. 4): 37–38.
- Ludlam C. Funding arrangements within the UK. Haemophilia 1998; 4 (Suppl. 1): 13-14.
- Fink A, Kosecoff J, Chasssin M et al. Consensus methods: characteristics and guidelines for use. American Journal of Public Health 1984; 74: 979–983.
- Netten A, Dennett J, Knight J. Unit costs of health and social care 1999. University of Kent, Canterbury, 1999. Personnel Social Services Research Unit.
- Monthly Index of Medical Specialities (MIMS), 2000 edition. London: Haymarket Publications Ltd, 2000.
- Department of Health. Drug Tariff, May 2000 edition. London: The Stationary Office, 2000.
- Hay CR, Baglin TP, Collins PW et al. The diagnosis and management of Factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO). British Journal of Haematology 2000; 111(1): 78–90.
- Inhibitor Subcommittee of the Association of Haemophilia Clinic Directors of Canada (AHCDC) (2000). Suggespptions for the management of Factor VIII inhibitors. Haemophilia; 6 (Suppl. 1): 52–59.
- Lee C. Funding rare and expensive treatments: the case of haemophilia. Haemophilia 1998; 4 (Suppl. 1): iii.
- Bolton-Maggs P. The doctor’s dilemma. Haemophilia 1998 4 (Suppl. 1): 4–5.
- Rivard G-E, Vick S. Economics of inhibitor treatment in Canada. Seminars in Haematology 1994; 31 (Suppl. 4): 41–43.
- Stewart AJ, Hanley JP, Ludlam CA. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated Factor VII in a patient with severe haemophilia A and an anti-Factor VIII inhibitor. Blood Coagulation and Fibrinolysis 1998; 9 (Suppl. 1): S93-S95.
- Lusher JM. Recombinant activated Factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment. Blood Coagulation and Fibrinolysis 1998; 9 (Suppl. 1): S111-S114.
- Aledort LM. Economic aspects of haemophilia care. Haemophilia 1999; 5: 216–219.